Oncternal Therapeutics announces first patient dosing in the fourth cohort from P-I/II study of ONCT-534. In the fourth cohort, patients will receive 300mg dose orally daily as compared to 160mg from third cohort of study
ONCT-534-101 study evaluates safety and tolerability, PK, and preliminary antitumor activity in mCRPC patients who are relapsed or refractory to approved ARPIs (incl. enzalutamide, abiraterone, apalutamide, and darolutamide)
Oncternal is expecting initial efficacy and safety data from study by the end of Q2’24
Ref: Oncternal Therapeutics | Image: Oncternal Therapeutics
Related News:- Oncternal Therapeutics Reverse Merges with GTx
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
